MedTrace Logo

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

NCT06044077 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1920

Last updated 2023-09-21

No results posted yet for this study

Summary

This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.

Conditions

  • Pneumococcal Disease

Interventions

BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

BIOLOGICAL

control pneumococcal polysaccharide vaccine

23-valent pneumococcal polysaccharide vaccine from Merck Sharp \& Dohme Corp

Sponsors & Collaborators

  • Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-08
Primary Completion
2024-03-08
Completion
2029-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06044077 on ClinicalTrials.gov